anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aconitate decarboxylase 1 (ACOD1) is the enzyme synthesizing itaconate, an immuno-regulatory metabolite tuning host-pathogen interactions. Such functions are achieved by affecting metabolic pathways regulating inflammation and microbe survival. However, at the whole-body level, metabolic roles of itaconate remain largely unresolved. By using multiomics-integrated approaches, here we show that ACOD1 responds to high-fat diet consumption in mice by promoting gut microbiota alterations supporting metabolic disease. Genetic disruption of itaconate biosynthesis protects mice against obesity, alterations in glucose homeostasis and liver metabolic dysfunctions by decreasing meta-inflammatory responses to dietary lipid overload. Mechanistically, fecal metagenomics and microbiota transplantation experiments demonstrate such effects are dependent on an amelioration of the intestinal ecosystem composition, skewed by high-fat diet feeding towards obesogenic phenotype. In particular, unbiased fecal microbiota profiling and axenic culture experiments point towards a primary role for itaconate in inhibiting growth of Bacteroidaceae and Bacteroides, family and genus of Bacteroidetes phylum, the major gut microbial taxon associated with metabolic health. Specularly to the effects imposed by Acod1 deficiency on fecal microbiota, oral itaconate consumption enhances diet-induced gut dysbiosis and associated obesogenic responses in mice. Unveiling an unrecognized role of itaconate, either endogenously produced or exogenously administered, in supporting microbiota alterations underlying diet-induced obesity in mice, our study points ACOD1 as a target against inflammatory consequences of overnutrition.
In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
The invention discloses an application of Sarcaboside B in the preparation of medicines for preventing and treating liver damage. The pharmacological study on the Sarcaboside B shows that the Sarcaboside B has a protection effect on mice acute liver injury induced by D-galactosamine (D-GalN) and CC14. Therefore, the Sarcaboside B can be used for the preparation of the medicines for preventing and treating liver damage or hepatitis. The application of the Sarcaboside B in the medicines for preventing and treating liver damage is disclosed by the invention for the first time. As the skeleton type of the Sarcaboside B belongs to a brand-new skeleton type, the Sarcaboside B has unexpected strong activity on liver damage treatment, and the possibility that other compounds provide revelation does not exist. The Sarcaboside B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for treating liver damage.
Subjects randomized to the SiFi arm will have an ultrasound-guided suprainguinal fascia iliaca single shot block performed preoperatively in the anesthesia block room with 40ml of 0.2% ropivacaine local anesthetic. This will be reduced to 30 ml in patients under 60 kg.
A computer-implemented system and method are described for a concurrent assessment of performance specifications and safety specifications of a product, such as a medical device. The computer-implemented system and method use a defined data structure for storing and linking specifications. The data structure stores use scenarios, action steps, design envelop parameters, performance specifications, hazards, and control specifications. Each performance specification, each hazard, and each control specification is configured to be linked to at least one of the action steps within the data structure. Additionally, each design envelope parameter is configured to be linked to one performance envelope parameter as an operating condition and/or a control envelope parameters as a control parameter within the data structure. The data structure accordingly uses hazards and control specifications as safety specifications to define a design envelop to limit performance specifications.
Patients burdened with ER+ advanced breast cancers and recruited in the trial will undergo an experimental 4FMFES-PET imaging within a 4-week interval of a medically-prescribed FDG-PET. The 4FMFES-PET procedure will be repeated at 6 and 18 months following the initial scan.
Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms in elderly men. Selective α1-adrenergic antagonists are now ﬁrst-line drugs in the medical management of BPH. This Hospital based randomized controlled clinical study designed to evaluate the efficacy of the new α1-blocker silodosin in the treatment of symptomatic benign prostatic hyperplasia (BPH).Ambulatory patients of age between 50 to 70 years, who were diagnosed as benign prostatic hyperplasia, were divided into two groups after fulfilling selection criteria. After informed consent \& random sampling by lottery, silodosin 8 mg was given to group A (study) \& tamsulosin 0.4 mg was given to group B (control). Total 149 patients were enrolled in this study but 8 patients were lost during follow up. Hence 141 patients completed the study, during the period of June 2017 to August 2018.
Weight-dependent one-time dosage of intravenous administration of iron(III)isomaltoside given prior to surgery. Dosage: \<50 kg body weight = 500 mg, 50-59 kg body weight = 600 mg, 60-59 kg body weight = 700 mg, 70-79 kg body weight = 800 mg, 80-89 kg body weight = 900 mg, and 90+ kg body weight = 1000 mg.
<P>PROBLEM TO BE SOLVED: To provide a beverage for treating cancer suppressing proliferation of cancer cells and killing the cancer cells for patients suffering from the cancer in a short period and accelerating restoring power of the cancer affected parts into normal cells by excellent medicinal effects of Duchesnea-chrysantha at a low cost without adverse effects and to provide a method for producing the same.  <P>SOLUTION: The beverage for treating the cancer comprises an extract from the Duchesnea-chrysantha. The extract from the Duchesnea-chrysantha is extracted with an alcohol. Furthermore, the beverage is characterized as including the Duchesnea-chrysantha in the alcohol [Shochu (low-class distilled spirits)]. On the other hand, a method for producing the beverage for treating the cancer is characterized as introducing the Duchesnea-chrysantha into the alcohol [the Shochu (low-class distilled spirits)] and allowing the Duchesnea-chrysantha to stand therein for one year.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
An oral form should supplant the injectable as soon as practicable. In the absence of bioavailability studies establishing bioequivalence between these two dosage forms the following guidelines for dosage are suggested. For an initial approximation of the total daily dose required, the parenteral dose administered in the preceding 24 hours may be used. Since this dose is only an initial estimate, it is recommended that careful monitoring of clinical signs and symptoms, including clinical efficacy, sedation, and adverse effects, be carried out periodically for the first several days following the initiation of switchover. In this way, dosage adjustments, either upward or downward, can be quickly accomplished. Depending on the patient’s clinical status, the first oral dose should be given within 12 to 24 hours following the last parenteral dose.
The composition includes a linear methylphenyl polysiloxane which suppresses the spontaneous flow of the composition without increasing the viscosity. A silicone composition for oral mucosa impression comprises: (A) 100 pts. wt. of an organopolysiloxane having at least two aliphatic unsaturated hydrocarbons in one molecule and having a viscosity at 25 deg C of 500-1,500 cS; (B) 0.1-20 pts. wt. of an organohydrogen polysiloxane having at least three hydrogen atoms directly bonded to a silicon atom in one molecule; (C) 10-500 ppm (based on the total amount of (A) and (B)) of a silicone-soluble platinum compound; (D) 1-20 pts. wt. of a linear methylphenyl polysiloxane having a viscosity at 25 deg C of 30-10,000 cS; (E) 10-200 pts. wt. of an inorganic filler; and (F) 0.5-5 pts. wt. of at least one nonionic surfactant.
This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. An implant is configured to fit inside of the middle meatus of a human nasal cavity. The implant includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate. The implant releases the mometasone furoate for more than 12 weeks. A second implant can also be provided configured to fit inside the middle meatus. The second implant also includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate, and releases the mometasone furoate for more than 12 weeks.
The aim of this study was to describe the 30-day mortality rate of adult patients with sepsis and septic shock in 6 intensive care units of 2 tertiary hospitals in Jordan. A prospective cohort design was used. Patients with sepsis and septic shock admitted to the medical and surgical intensive care units at 2 tertiary hospitals were followed up during the period between February 2022 and June 2022 (N = 148). Data were analyzed using SPSS, version 23. Moreover, descriptive statistics, chi-square, and binary logistic regression were used. Notably, 52.7% of patients with sepsis and septic shock died within 30 days of diagnosis of sepsis and septic shock. Sequential Organ Failure Assessment score and the history of having solid tumors significantly predicted the 30-day mortality rate. Moreover, 43 (29.0%) patients with sepsis and septic shock had positive blood cultures, and 46 (31.0%) had positive urine cultures. Patients with sepsis and septic shock have a notable mortality rate that can be predicted from total Sequential Organ Failure Assessment scores and from the history of having solid tumors. Early assessment and initiation of treatment for sepsis essentially would reduce the likelihood of progression of sepsis to septic shock and would reduce associated patients' mortality.
The safety and effectiveness of Halobetasol Propionate Topical Foam in patients younger than 12 years of age have not been established; therefore, use in children younger than 12 years is not recommended.

The safety and effectiveness of Halobetasol Propionate Topical Foam for the treatment of stable plaque psoriasis in subjects 12 to less than 18 years of age is supported by evidence from adequate and well-controlled studies in adults and from one open-label safety study in 24 subjects aged 12 to less than 18 years. Subjects 12 to less than 18 years with stable plaque psoriasis covering a minimum of 10% of the total body surface area at baseline were treated twice daily for 2 weeks with Halobetasol Propionate Topical Foam. Hypothalamic-pituitary adrenal (HPA) axis function (ACTH stimulation test) was evaluated in a subset of 23 subjects. After 2 weeks of treatment, 6 of 23 subjects (26.1%) experienced laboratory evidence of adrenal suppression (i.e., cortisol serum level of ≤18 µg/dL) that recovered upon retesting after at least 4 weeks of stopping the treatment [see Clinical Pharmacology (12.2)].

Because of higher skin surface area to body mass ratios, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse reactions including striae have been reported with use of topical corticosteroids in infants and children [see Warnings and Precautions (5.1)].

HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema [see Warnings and Precautions (5.1)].
The present invention discloses a novel milk-fermented product comprising a group of peptides. The peptides are composed from no.  1  to no.  7  of the figure that is selected from the group consisting of FIG.  11  to FIG.  18 . And the novel milk-fermented product is used for suppressing the reduction of bone mineral density. Therefore, the novel milk-fermented product could be a component of foods, nutrient supplement or medicine for treating or preventing osteoporosis.
Germline pathogenic variants (PVs) in the BRCA1 and BRCA2 genes confer elevated risks of breast, ovarian, and other cancers. Lynch syndrome (LS) is associated with increased risks of multiple cancer types including colorectal and uterine cancers. Current cancer risk mitigation strategies have focused on pharmacologic risk reduction, enhanced surveillance, and preventive surgeries. While these approaches can be effective, they stand to be improved on because of either limited efficacy or undesirable impact on quality of life. The current review summarizes ongoing investigational efforts in cancer risk prevention strategies for patients with germline PVs in BRCA1, BRCA2, or LS-associated genes. These efforts span radiation, surgery, and pharmacology including vaccine strategies. Understanding the molecular events involved in the premalignant to malignant transformation in high-risk individuals may ultimately contribute significantly to novel prevention strategies.
Untreated cardiac amyloidosis is accompanied with an impaired prognosis. Amyloidosis is often associated with ventricular hypertrophy which leads to severe heart failure and occurs frequently in conjunction with bradycardic or tachycardic malignant arrhythmia. Patients with degenerative aortic valve stenosis suffer more frequently from cardiac ATTR. However, it remains unclear whether the development of aortic stenosis is promoted by ATTR. Due to very similar symptoms (shortness of breath during physical exertion, reduced walking distance) diagnosis of aortic valve stenosis is more often diagnosed in a typical cohort of patients aged between 70-80 years but, in contrast, leads to underdiagnosis of patients with additional cardiac amyloidosis. Six to fifteen percent of patients with aortic valve replacement due to degenerative aortic valve stenosis exhibit a cardiac amyloidosis. Since cardiac amyloidosis without therapeutic intervention is associated with significantly reduced life expectancy, it can be assumed that these patients will not benefit to the same extent from the AVR alone as patients without ATTR. New therapeutic approaches for patients exhibiting ATTR lead to a reduction of mortality and hospitalizations. The primary aim of this study is to establish a simple ATTR screening tool in patients with planned AVR in the clinical routine and, furthermore, to compare the clinical course following AVR between patients with and without ATTR.
The inferior colliculus (IC) is a critical computational hub in the central auditory pathway. From its position in the midbrain, the IC receives nearly all the ascending output from the lower auditory brainstem and provides the main source of auditory information to the thalamocortical system. In addition to being a crossroads for auditory circuits, the IC is rich with local circuits and contains more than five times as many neurons as the nuclei of the lower auditory brainstem combined. These results hint at the enormous computational power of the IC, and indeed, systems-level studies have identified numerous important transformations in sound coding that occur in the IC. However, despite decades of effort, the cellular mechanisms underlying IC computations and how these computations change following hearing loss have remained largely impenetrable. In this review, we argue that this challenge persists due to the surprisingly difficult problem of identifying the neuron types and circuit motifs that comprise the IC. After summarizing the extensive evidence pointing to a diversity of neuron types in the IC, we highlight the successes of recent efforts to parse this complexity using molecular markers to define neuron types. We conclude by arguing that the discovery of molecularly identifiable neuron types ushers in a new era for IC research marked by molecularly targeted recordings and manipulations. We propose that the ability to reproducibly investigate IC circuits at the neuronal level will lead to rapid advances in understanding the fundamental mechanisms driving IC computations and how these mechanisms shift following hearing loss.
This study uses the "3+3" design to investigate the safety and determine the MTD of HLX07. Four dose levels of 800 mg, 1200 mg, 1500 mg and 1800 mg are planned for dose finding. Enrollment will continue until a maximum of 24 patients are enrolled.
Teratogenic Effects:

Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats at dosage levels of approximately 40 to 160 mg/kg/day (1 to 4 times the MRHD based on body surface area comparisons), and in mice at dosage levels of approximately 80 mg/kg/day (1 time the MRHD based on body surface area comparisons). Itraconazole has been shown to cross the placenta in a rat model. In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and/or macroglossia. 

Itraconazole oral solution contains the excipient hydroxypropyl-β-cyclodextrin (HP-β-CD). HP-β-CD has no direct embryotoxic and no teratogenic effect. 

There are no studies in pregnant women. Itraconazole should be used in pregnancy only if the benefit outweighs the potential risk. Highly effective contraception should be continued throughout Itraconazole therapy and for 2 months following the end of treatment.

During postmarketing experience, cases of congenital abnormalities have been reported (see ADVERSE REACTIONS: Postmarketing Experience).
Participants received cooking demonstrations and nutrition education, and were asked to use the seasoning provided (70% NaCl and 30% MSG Seasoning Mix) on vegetables and foods prepared. Then they recorded their food intake to compare vegetable intake to other groups.
INTRODUCTION: Caring for children with medical complexity (CMC) requires specialized knowledge and skills. However, no standardized curricula are used across training programs as institutions have varying needs and resources.
METHODS: We created a patient-focused, interactive curriculum for two CMC topics: feeding/nutrition and pain/irritability. We integrated the 45-minute sessions into morning protected patient-care time on an inpatient pediatric team at an urban tertiary care hospital. Targeted toward all pediatric residents and medical students rotating in inpatient pediatrics over a 12-month period, the sessions used a mix of didactic, discussion, and hands-on activities. Learners on one of two inpatient teams received the curriculum, while those on the other received a curriculum unrelated to CMC and served as a control group. Both groups completed retrospective pre/post self-assessments to evaluate self-efficacy with respect to the learning objectives.
RESULTS: Over the 12-month period, 72 surveys were completed for the feeding/nutrition session, 78 surveys for the pain/irritability session, and 42 control surveys. The intervention group saw the greatest increase in self-efficacy scores generally in the feeding/nutrition session. All eight learning objectives saw significant improvement in self-efficacy scores for the intervention group. There was significantly greater improvement in self-efficacy for the intervention group compared to the control for all eight learning objectives.
DISCUSSION: Through this patient-focused curriculum, learners had improved self-efficacy scores compared to the natural learning occurring on the inpatient service. The curriculum could be adapted to fit the needs of other institutions and provides a practical, hands-on approach to learning about caring for CMC.
Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
PURPOSE:To obtain a thromboxane A2 antagonist having low toxicity and high safety and useful as a platelet coagulation suppressing agent by using a phenoxyacetic acid derivative as an active component. CONSTITUTION:The objective agent can be prepared by using a compound of formula (R<1> to R<4> and R<7> are H or lower alkyl; R<5> is (substituted) phenyl; R<6> is (protected) carboxyl or OH; ring A is substituted phenylene; (m) is 0 or 1; (n) is 0-5; etc.) or its salt as an essential component, properly mixing the component with conventional drug preparation raw materials and forming the mixture in a drug form by conventional procedure. It can be used in the form of tablet, granule, capsule, suspension, emulsion, injection, etc. The daily dose of the agent is 0.01-50mg/kg. Useful for the therapy, amelioration and prevention of various diseases such as thrombosis and embolism, prevention of thrombosis in the extracorporeal circulation of blood, administration in the case of organ transplantation, therapy amelioration and prevention of myocardial ischemia, instable stenocardia, etc.
The control group will consist of a random sample of age- and sex-matched participants from the general population examined in the 5th Copenhagen City Heart Study, 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).